Amicus Therapeutics to Present at Leerink Swann Rare Disease Roundtable

CRANBURY, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Leerink Swann Rare Disease Roundtable in New York, NY on Wednesday, October 2, 2013 at 1:20 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

FOLD-G

CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 spellegrino@amicusrx.comSource:Amicus Therapeutics, Inc.